Cardiac Glycosides sales in Sweden have shown a notable decline from 2013 to 2023, with a peak value in 2014 at 2.3 million USD and a consistent downward trend reaching 1.3 million USD in 2023. The sales in 2023 witnessed no year-on-year growth from 2022, following a marginal uptick of 8.33% in 2022. Over the past five years, the compound annual growth rate (CAGR) was a negative -1.47%, indicating a persistent decrease in demand or market size for this pharmaceutical category.
Future trends to watch for:
- **Flat Growth**: From 2024 onwards, the sales are forecasted to stabilize at 1.3 million USD, showing no significant year-on-year variation.- **Market Saturation**: The zero growth implies market saturation or a shift towards alternative treatments.- **Regulatory and Innovation Impact**: Future sales could be influenced by new regulatory policies or innovations in cardiac treatment.
